drug sales – Talk Bio

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

1 week ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization

Gilead Exceeds COVID-19 Drug Sales Projections, Faces $1.75 Billion Loss on Trodelvy Trial Failure

6 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), drug sales, Failure (biologic function), Gilead, Trodelvy, Veklury

Gilead, COVID-19, Veklury, Trodelvy, drug sales, clinical trial failure

Eli Lilly’s Stock Plummets Following Q3 Earnings Miss and Reduced Revenue Forecast

6 months ago talkbio0Tagged Diabetes, Drops - Drug Form, drug sales, earnings, Eli, Eli Lilly, Obesity, Weight-Loss Agents

Eli Lilly, Q3 earnings, revenue forecast, stock drop, diabetes drugs, weight-loss drugs, obesity drug sales

AbbVie’s Skyrizi and Rinvoq Drive Growth, Counteracting Humira Decline

12 months ago talkbio0Tagged AbbVie, Drug Industry, drug sales, full-year outlook, Immunology, revenue growth, Rinvoq, Skyrizi

AbbVie, Skyrizi, Rinvoq, Humira, full-year outlook, pharmaceutical industry, revenue growth, drug sales, immunology drugs